Why Asia is the Emerging Epicenter for Global Biopharmaceutical Progress
From The Bio Report by Levine Media Group
March 4, 2026 · 40 min · Episode 164
About this episode
The episode discusses Asia's rise as a key player in biopharmaceutical innovation and drug development.
Asia is quickly becoming a powerhouse for biopharma innovation, changing ideas about where breakthrough science and fast, cost-efficient drug development happen. A new McKinsey & Company report shows how countries like China, Japan, and India are each building their own strengths across the drug development continuum. We spoke to Fangning Zhang, a partner in McKinsey’s Shanghai office, about what’s driving this shift, how it could make innovation more affordable, and why treating Asia as optional may mean missing the next wave of global R&D.
People in this episode
Guest: Fangning Zhang
Topics covered
- biopharmaceutical innovation
- drug development
- Asia
- R&D
- cost-efficient drug development
Keywords
- biopharma
- innovation
- drug development
- Asia
- McKinsey
- China
- Japan
- India
Mentioned in this episode
Organizations: McKinsey & Company
Places: China, Japan, India
More episodes of The Bio Report
- Stopping Shape-Shifting Tumors with a First-in-Class Epigenetic Drug · June 10, 2026 · 28 min
- Rewriting the Rules of Antibody Drug Design · June 3, 2026 · 38 min
- Mapping Cellular Stress Biology to Tackle Undruggable Targets · May 27, 2026 · 30 min
- Turning Abandoned Drugs into Breakthroughs · May 20, 2026 · 31 min
- Targeting Cancer Survival Genes in Solid Tumors · May 13, 2026 · 46 min
- Addressing Treatment Gaps in Gout · May 6, 2026 · 37 min
Explore listener stats, chart rankings, contacts and more on the The Bio Report podcast page.